Fredun Pharmaceuticals Limited's Board of Directors met on Wednesday, August 05, 2026, from 10:30 a.m. to 11:20 a.m. The meeting was conducted pursuant to Regulations 30 and 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

The Board considered, adopted, and approved the Un-Audited Financial Results of the Company for the quarter ended 30th June, 2026 along with the Limited Review Report issued by M/s. R.H. Nisar & Co, the Company's Statutory Auditor.

The trading window for trading in securities of the Company by insiders had closed on July 01, 2026, and remained closed until 48 hours after the declaration of the Board Meeting outcome, as per the company's intimation dated July 30, 2026.

Financial Results Overview

Consolidated Financials (Quarter Ended 30.06.2026)

  • Net Sales/Income from Operations: ₹22,775.55 lakhs (vs. ₹11,940.29 lakhs in Q1 FY26)
  • Other Operating Income: ₹49.24 lakhs (vs. ₹45.21 lakhs in Q1 FY26)
  • Total Income from Operations: ₹22,824.79 lakhs (vs. ₹11,985.50 lakhs in Q1 FY26)
  • Total Expenses: ₹20,769.60 lakhs (vs. ₹11,081.46 lakhs in Q1 FY26)
  • Profit Before Tax: ₹2,055.19 lakhs (vs. ₹904.04 lakhs in Q1 FY26)
  • Tax Expenses: ₹741.96 lakhs (vs. ₹227.46 lakhs in Q1 FY26)
  • Net Profit: ₹1,313.23 lakhs (vs. ₹676.58 lakhs in Q1 FY26)
  • Earnings Per Share (Basic): ₹23.82 (vs. ₹14.33 in Q1 FY26)
  • Earnings Per Share (Diluted): ₹22.19 (vs. ₹14.33 in Q1 FY26)

Standalone Financials (Quarter Ended 30.06.2026)

  • Net Sales/Income from Operations: ₹22,775.55 lakhs (vs. ₹11,940.29 lakhs in Q1 FY26)
  • Other Operating Income: ₹49.24 lakhs (vs. ₹45.21 lakhs in Q1 FY26)
  • Total Income from Operations: ₹22,824.79 lakhs (vs. ₹11,985.50 lakhs in Q1 FY26)
  • Total Expenses: ₹20,766.02 lakhs (vs. ₹11,081.46 lakhs in Q1 FY26)
  • Profit Before Tax: ₹2,058.77 lakhs (vs. ₹904.04 lakhs in Q1 FY26)
  • Tax Expenses: ₹741.96 lakhs (vs. ₹227.46 lakhs in Q1 FY26)
  • Net Profit: ₹1,316.81 lakhs (vs. ₹676.58 lakhs in Q1 FY26)
  • Earnings Per Share (Basic): ₹23.89 (vs. ₹14.33 in Q1 FY26)
  • Earnings Per Share (Diluted): ₹22.25 (vs. ₹14.33 in Q1 FY26)

Capital Structure

  • Paid-up Equity Share Capital (Face Value ₹10 each): ₹551.27 lakhs (55,127 shares)
  • Reserves excluding Revaluation Reserves: Not quantified in current period

Shareholding Pattern (Consolidated)

  • Public Shareholding: 30,55,637 shares (55.43%)
  • Promoter & Promoter Group Shareholding: 24,57,053 shares (44.57%)
  • All promoter shares are non-encumbered (100% of promoter holding)

Subsidiaries Included in Consolidated Results

The consolidated results include the following entities incorporated in India:

  • Fredun Retail Private Limited
  • One Pet Stop Private Limited
  • Wagr Retail Private Limited

Auditor Review

M/s. R.H. Nisar & Co (Firm Registration Number: 120895W) issued unmodified limited review reports on both the standalone and consolidated unaudited financial results. The review was conducted in accordance with Standard on Review Engagements (SRE) 2410 issued by ICAI. The auditor concluded that nothing came to their attention causing them to believe that the financial results contain any material misstatement.

Additional Notes

1. The financial results were prepared in accordance with Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013.

2. The company operates in a single segment: "Pharmaceutical and Healthcare".

3. Figures for the quarter ended March 31, 2026, are balancing figures between audited annual figures and published year-to-date unaudited figures up to the third quarter of previous financial year.

4. The Audit Committee reviewed and recommended the results for Board approval on August 5, 2026.